Target intelligence / Profile preview

Cryptosporidium parvum surface antigens (C. parvum surface antigens)

Target
C. parvum surface antigens
Molecular classification
Glycoprotein, Surface protein, Antigen, Adhesin
01

Overview

Cryptosporidium parvum surface antigens are a diverse group of proteins and glycoproteins expressed on the external membranes of the parasite during its various life stages, including oocysts, sporozoites, and merozoites. Key antigens such as the GP60 (gp40/15) complex, P23 (Cp23), and the thrombospondin-related anonymous protein (TRAP) are essential for the parasite's ability to excyst, move via gliding motility, and adhere to or invade host intestinal epithelial cells (Bouzid et al., 2013; O'Connor et al., 2007). These antigens are the primary targets for the host's humoral and cellular immune responses and are central to the pathogenesis of cryptosporidiosis, a significant cause of severe diarrheal disease worldwide, particularly in children and immunocompromised individuals (Checkley et al., 2015). While current small-molecule treatments like nitazoxanide target internal metabolic enzymes rather than surface proteins, these antigens are the focus of intensive research for passive immunotherapy and vaccine development. Experimental approaches using monoclonal antibodies and hyperimmune bovine colostrum aim to neutralize these antigens to prevent infection and reduce the severity of clinical symptoms (Hunt et al., 2002; Perryman et al., 1999).

Other names
GP60gp40/15P23Cp23TRAP-C1Cpgp40Cpgp15Cryptosporidium surface proteinsApical complex antigens
02

Mechanism of action

Neutralization of sporozoites and merozoites to prevent attachment and invasion of host intestinal epithelial cells, thereby interrupting the parasite life cycle.

03

Biological functions

Cell adhesionHost-parasite interactionParasite invasionGliding motilityExcystation
04

Disease associations

InfectionCryptosporidiosisDiarrheal disease
05

Safety considerations

Antigenic variation among different Cryptosporidium species and strainsImmune evasion mechanisms of the parasiteLimited efficacy of antibody-mediated neutralization in severely immunocompromised patients
06

Interacting drugs

Hyperimmune bovine colostrum

3 more in the full profile.

07

Biomarkers

Anti-Cp23 IgG antibodiesAnti-gp15 IgG antibodiesFecal Cryptosporidium antigen (ELISA/ICT)

Beyond the preview

Go deeper on Cryptosporidium parvum surface antigens (C. parvum surface antigens).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cryptosporidium parvum surface antigens (C. parvum surface antigens).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call